The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal North Shore Hospital
About this trial
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Eligibility criteria
Qualifiers
> 18 year of age
ECOG 0-2
Able to provide informed consent for the study
Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
Disqualifiers
No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
Does not fulfill PBS requirements for bevacizumab
Trial design
Treatments tested in this trial
- PSMA PET/CT scan
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Royal North Shore Hospital Status unavailable 2065, Saint Leonards, New South Wales
Australia
AustraliaSponsors and collaborators
Source ClinicalTrials.gov